Should I buy or sell Immix Biopharma stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immix Biopharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IMMX shares. View IMMX analyst ratings or view top-rated stocks .

What is Immix Biopharma's stock price target for 2024?

2 Wall Street analysts have issued 12 month price objectives for Immix Biopharma's shares. Their IMMX share price targets range from $14.00 to $14.00. On average, they predict the company's stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 332.1% from the stock's current price. View analysts price targets for IMMX or view top-rated stocks among Wall Street analysts .

How have IMMX shares performed in 2024?

Immix Biopharma's stock was trading at $6.92 at the beginning of the year. Since then, IMMX shares have decreased by 53.2% and is now trading at $3.24. View the best growth stocks for 2024 here .

When is Immix Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 25th 2024. View our IMMX earnings forecast .

When did Immix Biopharma IPO?

(IMMX) raised $23 million in an initial public offering on Thursday, December 16th 2021. The company issued 4,200,000 shares at $5.00-$6.00 per share.

Who are Immix Biopharma's major shareholders?

Immix Biopharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Private Advisor Group LLC (0.50%), Imprint Wealth LLC (0.17%), Jump Financial LLC (0.09%) and OLD National Bancorp IN (0.05%). Insiders that own company stock include Carey Ng, Helen C Adams, Ilya M Rachman, Jason Hsu, Magda Marquet, Melissa Jane Buchan and Sean Senn. View institutional ownership trends .

How do I buy shares of Immix Biopharma?

Shares of IMMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:IMMX

Immix Biopharma (IMMX) Stock Price, News & Analysis

$3.24

+0.01 (+0.31%)

(As of 02/9/2024 08:56 PM ET)

Compare

Today's Range: $3.13
▼
$3.48
50-Day Range: $2.83
▼
$7.27
52-Week Range: $1.40
▼
$7.75

Volume: 497,400 shs
Average Volume: 356,689 shs
Market Capitalization: $64.38 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $14.00

Get Immix Biopharma alerts:

Immix Biopharma MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 332.1% Upside
$14.00 Price Target
Short Interest: Healthy
2.88% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.80
Based on 10 Articles This Week
Insider Trading: Acquiring Shares
$266,770 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.80) to ($0.88) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.41 out of 5 stars

Medical Sector

545th out of 922 stocks

Pharmaceutical Preparations Industry

260th out of 429 stocks

3.5

Analyst's Opinion

Consensus Rating
Immix Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $14.00, Immix Biopharma has a forecasted upside of 332.1% from its current price of $3.24.
Amount of Analyst Coverage
Immix Biopharma has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.88% of the float of Immix Biopharma has been sold short.
Short Interest Ratio / Days to Cover
Immix Biopharma has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Immix Biopharma has recently increased by 3.10%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Immix Biopharma does not currently pay a dividend.
Dividend Growth
Immix Biopharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IMMX.

2.1

News and Social Media Coverage

News Sentiment
Immix Biopharma has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for Immix Biopharma this week, compared to 1 article on an average week.
Search Interest
Only 14 people have searched for IMMX on MarketBeat in the last 30 days. This is a decrease of -48% compared to the previous 30 days.
MarketBeat Follows
Only 6 people have added Immix Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Immix Biopharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $266,770.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
55.90% of the stock of Immix Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 3.97% of the stock of Immix Biopharma is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Immix Biopharma are expected to decrease in the coming year, from ($0.80) to ($0.88) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Immix Biopharma is -3.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Immix Biopharma is -3.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Immix Biopharma has a P/B Ratio of 3.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Immix Biopharma Stock (NASDAQ:IMMX)

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

IMMX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IMMX Stock News Headlines

February 8, 2024 | finance.yahoo.com

Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock

February 8, 2024 | finanznachrichten.de

Immix Biopharma, Inc.: Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis

February 12, 2024 | The Freeport Society (Ad)

Obama’s 2024 Confession

Barack Obama’s confession about the 2024 election just leaked online… In short, he’s worried Biden “could very well lose.” But before you think that means Trump will win… You should see the evidence I’ve found about an election shock that could come as soon as August 19th.

February 7, 2024 | markets.businessinsider.com

Immix Biopharma Signs Definitive $15M Titan Partnership Deal

February 7, 2024 | finance.yahoo.com

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis

February 6, 2024 | msn.com

Immix Biopharma Suspends Stock Offering Pending New Prospectus

February 5, 2024 | finance.yahoo.com

Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock

February 5, 2024 | finance.yahoo.com

Immix Biopharma Announces Proposed Public Offering of Common Stock

February 12, 2024 | The Freeport Society (Ad)

New Trump Bombshell

I believe Donald J. Trump will go down as America’s last Republican president. But NOT for the reasons you may think… If I’m right, the soul of this country will change forever…

January 24, 2024 | markets.businessinsider.com

Immix Biopharma Reveals FDA Labeling Change Notification For CAR-T Products

January 24, 2024 | finanznachrichten.de

Immix Biopharma, Inc.: Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products

January 24, 2024 | finance.yahoo.com

Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products

January 11, 2024 | finance.yahoo.com

Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Invest In Growth?

January 4, 2024 | finance.yahoo.com

Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board

December 18, 2023 | finance.yahoo.com

Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board

December 15, 2023 | finance.yahoo.com

Insider Spends US$267k Buying More Shares In Immix Biopharma

December 11, 2023 | finance.yahoo.com

Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023

November 30, 2023 | finance.yahoo.com

Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit

November 28, 2023 | finance.yahoo.com

What Makes Immix Biopharma, Inc. (IMMX) a Good Fit for 'Trend Investing'

November 24, 2023 | finance.yahoo.com

Pleasing Signs As A Number Of Insiders Buy Immix Biopharma Stock

November 22, 2023 | msn.com

Immix to assess cell therapy in Phase Ib/IIa AL amyloidosis trial

November 22, 2023 | finance.yahoo.com

Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis

November 21, 2023 | msn.com

FDA okays US clinical testing for Immix drug NXC-201

November 21, 2023 | markets.businessinsider.com

Immix Biopharma Announces FDA IND Clearance For CAR-T NXC-201

November 21, 2023 | finance.yahoo.com

Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing

November 6, 2023 | finance.yahoo.com

Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients

November 6, 2023 | finance.yahoo.com

Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients

See More Headlines

Receive IMMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immix Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 2/11/2024
Next Earnings (Estimated): 3/25/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:IMMX
CUSIP: N/A
CIK: 1873835
Web: www.immixbio.com
Phone: 310-651-8041
Fax: N/A
Employees: 9
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $14.00
High Stock Price Target: $14.00
Low Stock Price Target: $14.00
Potential Upside/Downside: +332.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.92)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-8,230,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -97.97%
Return on Assets: -85.47%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.90
Quick Ratio: 7.90

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.94 per share
Price / Book: 3.45

Miscellaneous

Outstanding Shares: 19,870,000
Free Float: 8,761,000
Market Cap: $64.38 million
Optionable: Optionable
Beta: 0.22

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Dr. Ilya Rachman M.B.A. (Age 51)
M.D., MBA, Ph.D., Co-Founder, CEO & Chairman
Comp: $637.5k
Mr. Gabriel Morris B.A. (Age 37)
CFO & Director
Comp: $637.5k
Mr. Sean Senn J.D.
M.B.A., M.Sc., MBA, MSc, Co-Founder
Dr. Vladimir P. Torchilin D.Sc. (Age 77)
MSE, Ph.D., Scientific Co-Founder
Mr. Ben H. Lyon J.D.
Executive VP & General Counsel
Dr. Graham Ross FFPM (Age 64)
M.D., Chief Medical Officer & Head of Clinical Development
Mr. Nandan Oza B.S. (Age 62)
Head of Chemistry, Manufacturing & Control
Dr. David Marks
Chief Medical Officer of Cell Therapy
Mr. Gerhard Bauer
Head of Cell Thearpy Manufacturing

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

IMMX Stock Analysis - Frequently Asked Questions

Should I buy or sell Immix Biopharma stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immix Biopharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IMMX shares.
View IMMX analyst ratings or view top-rated stocks.
What is Immix Biopharma's stock price target for 2024?: 2 Wall Street analysts have issued 12 month price objectives for Immix Biopharma's shares. Their IMMX share price targets range from $14.00 to $14.00. On average, they predict the company's stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 332.1% from the stock's current price.
View analysts price targets for IMMX or view top-rated stocks among Wall Street analysts.
How have IMMX shares performed in 2024?: Immix Biopharma's stock was trading at $6.92 at the beginning of the year. Since then, IMMX shares have decreased by 53.2% and is now trading at $3.24.
View the best growth stocks for 2024 here.
When is Immix Biopharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, March 25th 2024.
View our IMMX earnings forecast.

When did Immix Biopharma IPO?: (IMMX) raised $23 million in an initial public offering on Thursday, December 16th 2021. The company issued 4,200,000 shares at $5.00-$6.00 per share.
Who are Immix Biopharma's major shareholders?: Immix Biopharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Private Advisor Group LLC (0.50%), Imprint Wealth LLC (0.17%), Jump Financial LLC (0.09%) and OLD National Bancorp IN (0.05%). Insiders that own company stock include Carey Ng, Helen C Adams, Ilya M Rachman, Jason Hsu, Magda Marquet, Melissa Jane Buchan and Sean Senn.
View institutional ownership trends.
How do I buy shares of Immix Biopharma?: Shares of IMMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IMMX) was last updated on 2/12/2024 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial